evitria company logo
    • Recombinant Ab Production Service
    • Afucosylated Ab Service
    • Fc-silenced Ab Service
    • Bispecific Ab Production Service
    • HTP Production Service
    • Other Protein Production Service
  • Products
    • STR – True Fc Silencing Technology
    • GlymaxX® – Glycoengineering and ADCC Enhancement
    • Opti-mAb® – scFv Stabilization
    Our Technologies
    • About Evitria
    • Events
    • Partnerships
    • FAQs
    • Contact
  • Features

    • Transient Antibody Production
    • CHO cells – first choice for antibody production
    • Antibody reformatting and engineering
    • Scalability & Reproducibility

    Antibodies

    • Recombinant Antibodies
    • Afucosylated antibodies
    • Fc-silenced antibodies
    • Bispecific/multispecific antibodies

    Resources

    • Blog
    • Encyclopedia
    • Publications
Contact
  • Expression Services

    Recombinant Ab Production Service

    Afucosylated Ab Service

    Fc-silenced Ab Service

    Bispecific Ab Production Service

    Hight-Throughput Ab Production Service

    Other Protein Production

  • Products
  • Our Technologies

      Our Technologies

      STR – True Fc Silencing Technology

      GlymaxX® – Glycoengineering and ADCC Enhancement

      Opti-mAb® scFv Stabilization

      Our Technologies
  • About us

      About us

      About Evitria

      Events

      Partnerships

      FAQs

      Contact

  • Antibody Journal

      Antibody Journal

      Features

      Transient Antibody Production

      CHO cells – first choice for antibody production

      Antibody reformatting and engineering

      Scalability & Reproducibility

      Antibodies

      Recombinant Antibodies

      Afucosylated antibodies

      Fc-silenced antibodies

      Bispecific/multispecific antibodies

      Resources

      Blog

      Encyclopedia

      Publications

Let’s get in contact
  • LinkedIn
  • YouTube
  1. evitria
  2. 2024

2024

  • Afucosylated antibodies
  • Antibodies
  • Antibodies Journal
  • Bispecific antibodies
  • CHO Cells
  • High-Throughput
  • Monoclonal antibodies
  • News
  • Recombinant antibodies
  • Therapy Development

  • Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism

    technik Avatar
    December 14, 2025
  • A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice

    technik Avatar
    December 14, 2025
  • Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches

    technik Avatar
    December 14, 2025
  • SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models

    technik Avatar
    December 14, 2025
  • A metabolic crosstalk between liposarcoma and muscle sustains tumor growth

    technik Avatar
    December 14, 2025
  • A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

    technik Avatar
    December 14, 2025
  • Binding to the neonatal Fc receptor enhances the pathogenicity of anti-desmoglein-3 antibodies in keratinocytes

    technik Avatar
    December 14, 2025
  • ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome

    technik Avatar
    December 14, 2025
  • Identification of monoclonal antibodies from naive antibody phage-display libraries for protein detection in formalin-fixed paraffin-embedded tissues

    technik Avatar
    December 14, 2025
  • Skin Transcriptome Analysis Reveals Potential Molecular Mechanisms of S100A9 in Exacerbating the Inflammation in Rosacea

    technik Avatar
    December 14, 2025
  • Synergistically Acting on Myostatin and Agrin Pathways Increases Neuromuscular Junction Stability and Endurance in Old Mice

    technik Avatar
    March 30, 2025
  • Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection

    technik Avatar
    March 30, 2025
1 2
Next Page→

4 weeks from sequence to recombinant antibody.

  • LinkedIn
  • YouTube
  • Privacy Policy
  • About Evitria
  • HTML Sitemap

©2026 evitria ag

PowerEd by

We Value Your Privacy

This website uses cookies to enhance your browsing experience and provide personalized services. We require your consent to set these cookies on your device. Please note that we also use cookies from US companies that have not signed up to the EU-US data protection agreement.

Your Privacy

This site uses tracking technologies. You may opt in or opt out of the use of these technologies.

Marketing cookies and services are used to deliver personalized advertisements, promotions, and offers. These technologies enable targeted advertising and marketing campaigns by collecting information about users' interests, preferences, and online activities.

Analytics cookies and services are used for collecting statistical information about how visitors interact with website. These technologies provide insights into website usage, visitor behavior, and site performance to understand and improve the site and enhance user experience.

Personalization cookies enable the website to remember your choices and provide enhanced, more personal features. These cookies may track your preferences and show you relevant content based on your browsing patterns.

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedback, and other third-party features.

Essential cookies are necessary for the website to function properly. These cookies ensure basic functionalities and security features of the website.